Dollar Tree Free cash flow decreased by 59.6% to $391.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 201.9%, from $129.70M to $391.50M. Over 2 years (FY 2022 to FY 2025), Free cash flow shows an upward trend with a 6.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $331.30M | $141.20M | $285.10M | -$294.10M | -$177.70M | $1.16B | $401.60M | $1.38B | $379.20M | $0.00 | $444.20M | $110.30M | $129.70M | $15.60M | $0.00 | $968.50M | $391.50M |
| QoQ Change | — | -57.4% | +101.9% | -203.2% | +39.6% | +754.2% | -65.5% | +243.2% | -72.5% | -100.0% | — | -75.2% | +17.6% | -88.0% | -100.0% | — | -59.6% |
| YoY Change | — | — | -13.9% | — | — | +723.3% | +40.9% | +18.6% | -5.6% | — | — | -92.0% | -65.8% | — | -100.0% | +778.1% | +201.9% |